Clover Biopharmaceuticals (HKG:2197) received clearance from the US Food and Drug Administration for its RSV vaccine candidate, SCB-1019, with enrollment completed in the Phase I revaccination clinical trial, according to a filing with the Hong Kong bourse on Monday.
SCB-1019 is a new RSV vaccine using Trimer-Tag technology. It is designed to boost immunity in older adults aged 60 to 85 who previously received an initial dose of GSK's RSV vaccine.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments